Granzyme B expression system as well as preparation method and application thereof

By designing a granzyme B protein truncation and circular RNA expression system, and utilizing bacterial ribosome binding sites and liposome delivery, the specific expression of GZMB in bacteria was achieved, solving the problems of single-target antimicrobial drug resistance and healthy tissue damage, and achieving an efficient and safe bacterial sterilization effect.

CN120775828APending Publication Date: 2025-10-14SUN YAT SEN UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202510932031.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-07
Publication Date
2025-10-14

AI Technical Summary

Technical Problem

Most existing antibacterial drugs mainly act on a single target, which leads to the rapid development of bacterial resistance and makes it difficult to maintain long-term therapeutic effects. In addition, the protease activity of granzyme B is harmful to healthy tissues, limiting its clinical application.

Method used

A truncated granzyme B protein and its expression system were designed, using circular RNA and bacterial ribosome binding sites as translation regulatory elements, and a liposome delivery system to achieve specific expression of GZMB in bacteria, avoiding damage to mammalian cells.

Benefits of technology

GZMB has achieved efficient and precise bactericidal effects in bacteria, reducing the risk of bacterial resistance and toxic side effects on healthy tissues.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005486630200000011
    Figure HDA0005486630200000011
  • Figure HDA0005486630200000012
    Figure HDA0005486630200000012
  • Figure HDA0005486630200000021
    Figure HDA0005486630200000021
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a granzyme B expression system as well as a preparation method and application thereof. According to the invention, granzyme B with bactericidal activity is screened out, a corresponding expression vector is designed by adopting circular RNA, a bacterium-specific ribosome binding site (RBS) is taken as a protein translation regulation and control element, and a Lipid nano-particle (LNP) is taken as a delivery vector, so that efficient delivery of the circular RNA for coding GZMB and specific expression of GZMB in bacteria are realized. According to the strategy, efficient delivery and specific expression of circRNA for coding GZMB in bacteria are achieved, and a safe and accurate scheme is provided for GZMB antibacterial treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a granzyme B expression system and a preparation method and application thereof. Background Art

[0002] With the widespread use of antimicrobial drugs worldwide, bacterial resistance has become a major public health challenge. Traditional antimicrobial drug development has long followed the "single target" paradigm, believing that high target specificity can reduce toxic side effects. However, practice has shown that antimicrobial drugs targeting a single target often quickly induce high-level drug resistance and are difficult to maintain long-term efficacy [1,2]. Commonly used antibiotics in clinical practice interfere with protein synthesis by binding to the ribosomal 30S / 50S subunit, including the initiation stage (linezolid), aminoacyl-tRNA binding (tetracyclines), peptide chain elongation (chloramphenicol), ribosome movement (aminoglycosides), etc. However, the single target characteristics of such drugs are prone to rapid development of drug resistance due to target mutations. Even new single-target drugs such as mupirocin (isoleucyl-tRNA synthetase inhibitor) and acyldepsipeptide (ClpP activator) find it difficult to break through this limitation [3]. At present, almost all common clinical pathogens show varying degrees of resistance to existing antimicrobial drugs. Studies have shown that “multi-target” antimicrobial drugs can not only act on multiple key biosynthetic or metabolic pathways simultaneously, reducing the risk of drug resistance caused by single mutations, but also optimize pharmacokinetic properties and improve patient compliance [4]. Therefore, the development of new antimicrobial drugs with “multi-target” synergistic effects has become the key to breaking the deadlock.

[0003] Granzyme B (GZMB) is a serine protease secreted by cytotoxic T lymphocytes and natural killer cells (NK cells). Recent studies have shown that GZMB targets and degrades ribosomal proteins, tRNA synthetases, molecular chaperones, and the Clp system through a "microptosis" mechanism, and destroys multiple core metabolic pathways of bacteria, such as oxidative metabolism and anaerobic glycolysis, thereby achieving a "multi-target" synergistic bactericidal effect. More importantly, the bactericidal targets of GZMB cover a wide range of classic targets of various traditional antibiotics. Therefore, in the process of anti-infection, it not only significantly increases the threshold for bacteria to develop drug resistance, but also has broad-spectrum bactericidal potential [3]. However, the protease activity of GZMB can lead to serious side effects such as basement membrane destruction, epithelial barrier dysfunction, and inflammatory cytokine storm, which seriously limits its clinical application [5].

[0004] Therefore, it is necessary to develop a GZMB expression system that has low toxicity to healthy tissues and can specifically exert toxic effects in bacteria.

[0005] [1]Gray,DAand M.Wenzel,Multitarget Approaches againstMultiresistant Superbugs.ACS Infect Dis,2020.6(6):p.1346-1365.

[0006] [2]Chopra, I., Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents. Curr Opin Investig Drugs, 2007.8(8):p.600-7.

[0007] [3] Dotiwala, F., et al., Granzyme B Disrupts Central Metabolism and Protein Synthesis in Bacteria to Promote an Immune Cell Death Program. Cell, 2017.171(5):p.1125-1137.e11.

[0008] [4]Feng, J., et al., Multitarget antibacterial drugs: An effective strategy to combat bacterial resistance. Pharmacology&Therapeutics, 2023.252:p.108550.

[0009] [5]Richardson, KC, et al., Granzyme B in aging and age-relatedpathologies. Trends in Molecular Medicine, 2024.30(12):p.1165-1179. Summary of the Invention

[0010] In order to achieve the above-mentioned purpose of the present invention, the technical solution adopted by the present invention is:

[0011] In a first aspect, the present invention provides a truncated form of a granzyme B protein, wherein the amino acid sequence of the truncated form of the granzyme B protein is shown in SEQ ID NO: 3.

[0012] In a second aspect of the present application, a DNA molecule is provided, which comprises a bacterial ribosome binding site, a circularization sequence, and a sequence encoding the truncated proteinase B of the first aspect of the present application.

[0013] In some embodiments of the present application, the sequence encoding the truncated proteinase B of the first aspect of the present application is shown in SEQ ID NO: 3.

[0014] In some embodiments of the present application, the restriction enzyme sites are XbaI and XhoI. Other restriction enzyme sites in the art can also be used.

[0015] In some embodiments of the present application, the sequence of the ribosome binding site is shown in SEQ ID NO: 1.

[0016] In some embodiments of the present application, the circularization sequence is the T4 phage td gene intron circularization sequence, which is shown in SEQ ID NO: 8, 9.

[0017] In some embodiments of the present application, the sequence of the DNA molecule is shown in SEQ ID NO: 18.

[0018] In a third aspect of the present application, an RNA molecule is provided, which comprises a bacterial ribosome binding site, a circularization sequence, and a sequence encoding the truncated proteinase B of the first aspect of the present application, or the fusion protein of the second aspect of the present application.

[0019] In some embodiments of the present application, the RNA molecule is a linear RNA molecule or the RNA molecule is a circular RNA molecule obtained by circularization treatment.

[0020] In some embodiments of the present application, the RNA molecule is transcribed from a DNA molecule with a sequence shown in SEQ ID NO: 18.

[0021] In a fourth aspect of the present application, a method for preparing the RNA molecule of the third aspect of the present application is provided, which is transcribed from the DNA molecule of the second aspect of the present application.

[0022] In some embodiments of the present application, the method further comprises a circularization step after transcription.

[0023] In a fifth aspect of the present application, a vector is provided, which comprises the DNA molecule of the third aspect of the present application, and a vector backbone.

[0024] In some embodiments of the present application, the vector backbone comprises pET28a, pRMC2. Other conventional vectors in the art can also achieve the effects of the present application.

[0025] The sixth aspect of the present invention provides a delivery system comprising the RNA molecule according to the fourth aspect of the present invention and liposomes.

[0026] In some embodiments of the present invention, the liposomes include at least one of 1-octylnonyl 8-[(2-hydroxyethyl)[6-oxo-6-(undecanyloxy)hexyl]amino]-octanoate (SM-102), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), DC-cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[(polyethylene glycol)-2000] (DSPE-PEG2000).

[0027] In some embodiments of the present invention, the liposomes are composed of SM-102, DSPC, cholesterol and DSPE-PEG2000.

[0028] In some embodiments of the present invention, the molar ratio of SM-102, DSPC, cholesterol and DSPE-PEG2000 is (25-75):(5-20):(20-50):(1-5).

[0029] The seventh aspect of the present invention provides use of the RNA molecule of the fourth aspect of the present invention and the delivery system of the seventh aspect of the present invention in the preparation of a sterilization product.

[0030] In some embodiments of the invention, the product comprises a pharmaceutical product.

[0031] In some embodiments of the present invention, the sterilization product targets Escherichia coli, Staphylococcus aureus, Listeria, Mycobacterium tuberculosis and other common pathogens in the art.

[0032] The eighth aspect of the present invention provides a bactericidal drug.

[0033] In some embodiments of the present invention, the drug comprises the RNA molecule of the third aspect of the present invention, the delivery system of the fourth aspect of the present invention, and a pharmaceutically acceptable excipient.

[0034] In some embodiments of the present invention, the pharmaceutically acceptable excipients include at least one of solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrities, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoaming agents, thickeners, inclusion agents, humectants, absorbents, diluents, flocculants and deflocculating agents, filter aids, release retardants, and carriers.

[0035] The above-mentioned pharmaceutically acceptable excipients are generally recognized for this purpose and as inactive ingredients of medicaments. A compilation of pharmaceutically acceptable excipients can be found in reference books such as the Handbook of Pharmaceutical Excipients (2nd edition, edited by A. Wade and PJ Weller; published by the American Pharmaceutical Association, Washington and The Pharmaceutical Gess, London, 1994); and the Pharmacopoeia of the People's Republic of China - List of Pharmaceutical Excipients.

[0036] In some embodiments of the present invention, the dosage form of the drug includes at least one of powder, tablet, granule, sustained-release agent, solution, dry suspension, effervescent tablet, emulsion, suspension, and drops.

[0037] The beneficial effects of the present invention are:

[0038] The present invention screened a granzyme B protein sequence with bactericidal activity and designed a corresponding expression vector using circular RNA. Using a bacterial-specific ribosome binding site (RBS) as a protein translation regulatory element and liposomes (LNPs) as delivery vehicles, the researchers achieved efficient delivery of GZMB-encoding circular RNA and specific expression of GZMB in bacteria. This strategy achieves efficient delivery and specific expression of GZMB-encoding circRNA in bacteria, providing a safe and precise solution for GZMB antibacterial therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] The present invention will be further described below with reference to the accompanying drawings and embodiments, in which:

[0040] Figure 1 This is the verification result that GZMB has a bactericidal effect.

[0041] Figure 2 The expression of eGFP in E. coli mediated by RBS; (AB) expression of eGFP with RBS as the translation initiation element; (CD) expression of eGFP with Kozak sequence as the translation initiation element.

[0042] Figure 3 Schematic diagram of the circular RNA structure encoding eGFP.

[0043] Figure 4RBS cannot mediate the expression of eGFP in 293T; (AB) expression of eGFP with CVB3 as the translation initiation element; (CD) expression of eGFP with RBS as the translation initiation element.

[0044] Figure 5 Verification of LNP delivery effect.

[0045] Figure 6 Schematic diagram of the structure of the GZMB-encoding circular RNA specifically expressed in bacteria.

[0046] Figure 7 Characterization of lin-RBS-GZMB-LNP and circ-RBS-GZMB-LNP; (A) Particle size of lin-RBS-GZMB-LNP and circ-RBS-GZMB-LNP (n=3); (B) Polydispersity index (PDI) of lin-RBS-GZMB-LNP and circ-RBS-GZMB-LNP (n=3); (C) Zeta potential of lin-RBS-GZMB-LNP and circ-RBS-GZMB-LNP (n=3).

[0047] Figure 8 Verification of the bactericidal effect of lin-RBS-GZMB-LNP and circ-RBS-GZMB-LNP; (AB) E. coli growth and colony number statistics (n=3); (CD) S. aureus growth and colony number statistics (n=3). ** indicates P value < 0.01; **** indicates P value < 0.0001; ns indicates no significant difference.

[0048] Figure 9 Immunoreactivity detection of lin-RBS-GZMB-LNP and circ-RBS-GZMB-LNP. Total RNA was extracted from mouse macrophage RAW 264.7 (A), mouse muscle cells C2C12 (B), and human embryonic kidney 293T cells (C) after transfection, and the expression of inflammatory factors was detected (n = 3). **** indicates P value < 0.0001; ns indicates no significant difference. DETAILED DESCRIPTION

[0049] The following will clearly and completely describe the concept and technical effects of the present invention in conjunction with the embodiments to fully understand the purpose, features and effects of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0050] Because GZMB exerts perforin-independent functions, it can cause chronic tissue damage, inflammation, and impaired healing in the extracellular environment. This property creates the risk of damaging healthy host tissue while simultaneously killing pathogens. Therefore, the key to the success of GZMB-based drugs lies in establishing a targeted expression system that ensures the protease precisely targets bacteria without damaging mammalian cells.

[0051] To address the above problems, the present invention uses circular RNA (circRNA) as an expression vector to construct an expression form of GZMB protein targeted for bacterial expression.

[0052] Example 1 Construction of GZMB expression sequence

[0053] In this example, a GZMB expression plasmid, pET28a(+)-RBS-GZMB, was constructed to test its bactericidal activity against Escherichia coli. The sequence, including the bacterial ribosome binding site (RBS) (SEQ ID NO: 1) and the GZMB coding sequence, was obtained from Genbank accession number NM_004131.6 (891 bp in total), from positions 31 to 774 of the human GZMB protein gene sequence (nucleotide sequence as SEQ ID NO: 2; amino acid sequence as SEQ ID NO: 3). The complete sequence is shown in SEQ ID NO: 4.

[0054] RBS binding site: TTTGTTTAACTTTAAGAAGGAGA (SEQ ID NO: 1).

[0055] GZMB (nucleotides 31-774):

[0056] ATGCAACCAATCCTGCTTCTGCTGGCCTTCCTCCTGCTGCCCAGGGCAGATGCAGGGGAGATCATCGGGGGACATGAGGCCAAGCCCCACTCCCGCCCCTACATGGCTTATCTTATGATCTGGGATCAGAAGTCTCTGAAGAGGTGCGGTGGCTTCCTGATACGAGACGACTTCGTGCTGACAGCTGCTCACTGTTGGGGAAGCTCCATAAATGTCACCTTGGGGGCCCACAATATCAAAGAACAGGAGCCGACCCAGCAGTTTATCCCTGTGAAAAGACCCATCCCCCATCCAGCCTATAATCCTAAGAACTTCTCCAACGACATCATGCTACTGCAGCTGGAGAGAAAGGCCAAGCGGACCAGAGCTGTGCAGCCCCTCAGGCTACCTAGCAACAAGGCCCAGGTGAAGCCAGGGCAGACATGCAGTGTGGCCGGCTGGGGGCAGACGGCCCCCCTGGGAAAACACTCACACACACTACAAGAGGTGAAGATGACAGTGCAGGAAGATCGAAAGTGCGAATCTGACTTACGCCATTATTACGACAGTACCATTGAGTTGTGCGTGGGGGACCCAGAGATTAAAAAGACTTCCTTTAAGGGGGACTCTGGAGGCCCTCTTGTGTGTAACAAGGTGGCCCAGGGCATTGTCTCCTATGGACGAAACAATGGCATGCCTCCACGAGCCTGCACCAAAGTCTCAAGCTTTGTACACTGGATAAAGAAAACCATGAAACGCTACTAA (SEQ ID NO: 2).

[0057] GZMB (amino acids 1-247):

[0058] MQPILLLLAFLLLPRADAGEIIGGHEAKPHSRPYMAYLMIWDQKSLKRCGGFLIRDDFVLTAAHCWGSSINVTLGAHNIKEQEPTQQFIPVKRPIPHPAYNPKNFSNDIMLLQLERKAKRTRAVQPLRLPSNKAQVKPGQTCSVAGWGQTAPLGKHSHTLQEVKMTVQEDRKCESDLRHYYDSTIELCVGDPEIKKTSFKGDSGGPLVCNKVAQGIVSYGRNNGMPPRACTKVSSFVHWIKKTMKRY(SEQ ID NO:3)。

[0059] RBS+GZMB(31-774核苷酸)

[0060] TTTGTTTAACTTTAAGAAGGAGATATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGCAACCAATCCTGCTTCTGCTGGCCTTCCTCCTGCTGCCCAGGGCAGATGCAGGGGAGATCATCGGGGGACATGAGGCCAAGCCCCACTCCCGCCCCTACATGGCTTATCTTATGATCTGGGATCAGAAGTCTCTGAAGAGGTGCGGTGGCTTCCTGATACGAGACGACTTCGTGCTGACAGCTGCTCACTGTTGGGGAAGCTCCATAAATGTCACCTTGGGGGCCCACAATATCAAAGAACAGGAGCCGACCCAGCAGTTTATCCCTGTGAAAAGACCCATCCCCCATCCAGCCTATAATCCTAAGAACTTCTCCAACGACATCATGCTACTGCAGCTGGAGAGAAAGGCCAAGCGGACCAGAGCTGTGCAGCCCCTCAGGCTACCTAGCAACAAGGCCCAGGTGAAGCCAGGGCAGACATGCAGTGTGGCCGGCTGGGGGCAGACGGCCCCCCTGGGAAAACACTCACACACACTACAAGAGGTGAAGATGACAGTGCAGGAAGATCGAAAGTGCGAATCTGACTTACGCCATTATTACGACAGTACCATTGAGTTGTGCGTGGGGGACCCAGAGATTAAAAAGACTTCCTTTAAGGGGGACTCTGGAGGCCCTCTTGTGTGTAACAAGGTGGCCCAGGGCATTGTCTCCTATGGACGAAACAATGGCATGCCTCCACGAGCCTGCACCAAAGTCTCAAGCTTTGTACACTGGATAAAGAAAACCATGAAACGCTACTAA(SEQ ID NO:4)。

[0061] 1、pET28a(+)-RBS-GZMB的构建:

[0062] 1) SEQ ID NO: 4 was synthesized by Sangon Biotech (Shanghai) Co., Ltd. and double-digested with XbaI and XhoI enzymes, and recovered using a gel excision recovery kit (Yeasen, 19101ES70).

[0063] 2) The pET28a(+) plasmid was double-digested with XbaI and XhoI enzymes, and the fragments were recovered by gel excision using a gel recovery kit (Yeasen, 19101ES70).

[0064] 3) Use T4 DNA ligase to ligate the fragments at 16°C for 2 hours. Use the ligation solution to directly transform competent E. coli (DH5α) cells. Plate the transformed E. coli (DH5α) cells on solid LB medium supplemented with 50 μg / mL kanamycin and culture overnight at 37°C. Pick a single colony from the culture, extract the plasmid, and sequence it. The plasmid that is sequenced correctly is pET28a(+)-RBS-GZMB.

[0065] 2. Transform pET28a(+)-RBS-GZMB into E. coli (BL21) and culture overnight.

[0066] 3. Pick a single colony and inoculate it into 10 mL of liquid LB medium containing 50 μg / mL kanamycin. Incubate at 37°C on a shaker at 220 rpm until the OD600 reaches approximately 0.4. Add IPTG to a final concentration of 0.1 mM, 0.5 mM, or 1 mM to induce GZMB expression. Samples were collected every 2 hours and the OD600 absorbance was measured to determine the bactericidal efficacy of GZMB.

[0067] 4. Staphylococcus aureus sterilization test

[0068] 1) Construct pRMC2-RBS-GZMB by referring to the above method.

[0069] 2) Transform pRMC2-RBS-GZMB into S. aureus (RN4220); plate and culture overnight.

[0070] 3) Pick a single colony and inoculate it into 10 mL of liquid LB medium containing 50 μg / mL ampicillin. Incubate at 37°C on a shaker at 220 rpm until the OD600 reaches approximately 0.4. Add tetracycline at a final concentration of 50 ng / μL, 100 ng / μL, or 200 ng / μL to induce GZMB expression. Samples were collected every 2 hours and the OD600 absorbance was measured to determine the bactericidal efficacy of GZMB.

[0071] 5. Experimental results

[0072] The experimental results are as follows Figure 1 As shown, GZMB (SEQ ID NO: 3) has antibacterial activity.

[0073] Example 2 Verification of Specific Expression of RBS Expression Elements in Bacteria

[0074] In this example, a bacteria-specific expression vector was constructed to verify the specificity of the bacterial ribosome binding site (RBS) as a translation regulatory element.

[0075] 1. Construction of RBS-specific detection plasmid pET28a(+)-RBS-eGFP:

[0076] 1) This plasmid contains a bacterial ribosome binding site (RBS) (SEQ ID NO: 1) and a green fluorescent protein (eGFP) (SEQ ID NO: 5) coding sequence inserted into the backbone. The complete inserted sequence is shown in SEQ ID NO: 6 (synthesized by Sangon Biotech (Shanghai) Co., Ltd.). SEQ ID NO: 6 was double-digested with XbaI and XhoI enzymes and recovered using a gel extraction kit (Yeasen, 19101ES70).

[0077] 2) The pET28a(+) plasmid was double-digested with XbaI and XhoI enzymes, and the fragments were recovered by gel excision using a gel recovery kit (Yeasen, 19101ES70).

[0078] 3) Use T4 DNA ligase to ligate the fragments at 16°C for 2 hours. Use the ligation solution to directly transform competent E. coli (DH5α) cells. Plate the transformed E. coli (DH5α) cells on solid LB medium supplemented with 50 μg / mL kanamycin and culture overnight at 37°C. Pick a single colony from the culture, extract the plasmid, and sequence it. The plasmid that is sequenced correctly is pET28a(+)-RBS-eGFP.

[0079] The above sequence is as follows:

[0080] eGFP:

[0081] ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA(SEQ ID NO:5)。

[0082] RBS-eGFP:

[0083] TTTGTTTAACTTTAAGAAGGAGATATACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA(SEQID NO:6)。

[0084] 2、对照载体pET28a(+)-Kozak-eGFP的构建

[0085] 在pET28a(+)-RBS-eGFP的基础上,利用同源重组连接将RBS替换成Kozak序列(GCCACC),完整的序列如SEQ ID NO:7所示。

[0086] 1) SEQ ID NO: 7 was synthesized by Sangon Biotech (Shanghai) Co., Ltd. and double-digested with XbaI and XhoI enzymes, and recovered using a gel excision recovery kit (Yeasen, 19101ES70).

[0087] 2) The pET28a(+) plasmid was double-digested with XbaI and XhoI enzymes, and the fragments were recovered by gel excision using a gel recovery kit (Yeasen, 19101ES70).

[0088] 3) Use T4 DNA ligase to ligate the fragments at 16°C for 2 hours. Use the ligation solution to directly transform competent E. coli (DH5α) cells. Plate the transformed E. coli (DH5α) cells on solid LB medium supplemented with 50 μg / mL kanamycin and culture overnight at 37°C. Pick a single colony from the culture, extract the plasmid, and sequence it. The plasmid that is sequenced correctly is pET28a(+)-Kozak-eGFP.

[0089] Kozak-eGFP:

[0090] GCCACCTATACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAA(SEQ ID NO:7)。

[0091] 3、表达检测

[0092] The pET28a(+)-RBS-eGFP and pET28a(+)-Kozak-eGFP plasmids were transformed into E.coli (BL21) respectively. The specific steps are as follows: 1 μg of plasmid was mixed with 100 μL of E.coli (BL21) competent cells and incubated on ice for 30 minutes. Heat shock at 42°C for 90 seconds, and then immediately placed on ice for 2 minutes. Add 1 mL of LB medium and culture at 37°C for 1 hour. Take 100 μL of transformed DH5α cells and spread them on solid LB medium containing 50 μg / mL kanamycin and culture them at 37°C overnight. Pick a single colony from the culture medium, suspend it in 5 mL of LB medium containing 50 μg / mL kanamycin and culture it to OD600 = 0.4-0.6, then add IPTG (final concentration 0.1 mM) to induce for 1 hour and observe the fluorescence of E.coli (BL21). The results are as follows Figure 2 shown.

[0093] After transformation into E. coli (BL21) and induction with IPTG, only the RBS vector could drive eGFP expression ( Figure 2 AB), while the Kozak vector has no fluorescent signal ( Figure 2 CD), confirming that RBS has prokaryotic translation initiation function.

[0094] Example 3 Construction of circular RNA expression system

[0095] 1. Construction of RBS-specific detection plasmid pET28a(+)-circ-RBS-eGFP

[0096] The plasmid includes a bacterial ribosome binding site (RBS) (SEQ ID NO: 1), a green fluorescent protein (eGFP) (SEQ ID NO: 5) coding sequence, and a T4 phage td gene intron cyclization sequence (SEQ ID NO: 8 and SEQ ID NO: 9). The complete inserted sequence is shown in SEQ ID NO: 10.

[0097] 1) SEQ ID NO: 10 was synthesized by Sangon Biotech (Shanghai) Co., Ltd. and double-digested with XbaI and XhoI enzymes, and recovered using a gel excision recovery kit (Yeasen, 19101ES70).

[0098] 2) The pET28a(+) plasmid was double-digested with XbaI and XhoI enzymes, and the fragments were recovered by gel excision using a gel recovery kit (Yeasen, 19101ES70).

[0099] 3) Ligate the fragment using T4 DNA ligase at 16°C for 2 hours. Use the ligation solution to directly transform competent E. coli (DH5α) cells. Plate the transformed E. coli (DH5α) cells on solid LB medium supplemented with 50 μg / mL kanamycin and culture overnight at 37°C. Single colonies were picked from the culture medium, and the plasmid was extracted and sequenced. The plasmid that was sequenced correctly was pET28a(+)-circ-RBS-eGFP.

[0100] T4 phage td gene intron circularization sequence:

[0101] AGACCCTCGAATGGAATTGGTTCTACATAAATGCCTAACGACTATCCCTTTGGGGAGTAGGGTCAAGTGACTCGAAACGATAGACAACTTGCTTTAACAAGTTGGAGATATAGTCTGCTCTGCATGGTGACATGCAGCTGGATATAATTCCGGGGTAAGATTAACGACCTTATCTGAACATAATGCT (SEQ ID NO: 8);

[0102] TTGGGTTAATTGAGGCCTGAGTATAAGGTGACTTATACTTGTAATCTATCTAAACGGG GAACCTCTCTAGTAGACAATCCCGTGCTAAATTGTAGGACTAATTCCATTTATCAGATTTC TAGA (SEQ ID NO: 9).

[0103] Full sequence:

[0104]

[0105] 2. Construction of control plasmid pET28a(+)-circ-CVB3-eGFP

[0106] Based on pET28a(+)-circ-RBS-eGFP, RBS was replaced with the CVB3 sequence (SEQ ID NO: 11) by homologous recombination. The complete inserted sequence is shown in SEQ ID NO: 12.

[0107] 1) SEQ ID NO: 12 was synthesized by Sangon Biotech (Shanghai) Co., Ltd. and double-digested with XbaI and XhoI enzymes, and recovered using a gel excision recovery kit (Yeasen, 19101ES70).

[0108] 2) The pET28a(+) plasmid was double-digested with XbaI and XhoI enzymes, and the fragments were recovered by gel excision using a gel recovery kit (Yeasen, 19101ES70).

[0109] 3) Ligate the fragment using T4 DNA ligase at 16°C for 2 hours. Transform the ligation solution directly into competent E. coli (DH5α) cells. Plate the transformed E. coli (DH5α) cells on solid LB medium supplemented with 50 μg / mL kanamycin and culture overnight at 37°C. Single colonies were picked from the culture medium, and the plasmids were extracted and sequenced. The plasmid that was sequenced correctly was pET28a(+)-circ-CVB3-eGFP.

[0110] CVB3 sequence:

[0111] CAGCCTGTGGGTTGATCCCACCCACAGGCCCATTGGGCGCTAGCACTCTGGTATCACGGTACCTTTGTGCGCCTGTTTTATACCCCCTCCCCCAACTGTAACTTAGAAGTAACACACACCGATCAACAGTCAGCGTGGCACACCAGCCACGTTTTGATCAAGCACTTCTGTTACCCCGGACTGAGTATCAATAGACTGCTCACGCGGTTGAAGGAGAAAGCGTTCGTTATCCGGCCAACTACTTCGAAAAACCTAGTAACACCGTGGAAGTTGCAGAGTGTTTCGCTCAGCACTACCCCAGTGTAGATCAGGTCGATGAGTCACCGCATTCCCCACGGGCGACCGTGGCGGTGGCTGCGTTGGCGGCCTGCCCATGGGGAAACCCATGGGACGCTCTAATACAGACATGGTGCGAAGAGTCTATTGAGCTAGTTGGTAGTCCTCCGGCCCCTGAATGCGGCTAATCCTAACTGCGGAGCACACACCCTCAAGCCAGAGGGCAGTGTGTCGTAACGGGCAACTCTGCAGCGGAACCGACTACTTTGGGTGTCCGTGTTTCATTTTATTCCTATACTGGCTGCTTATGGTGACAATTGAGAGATCGTTACCATATAGCTATTGGATTGGCCATCCGGTGACTAATAGAGCTATTATATATCCCTTTGTTGGGTTTATACCACTTAGCTTGAAAGAGGTTAAAACATTACAATTCATTGTTAAGTTGAATACAGCAAA(SEQ ID NO:11)。

[0112] 完整序列:

[0113]

[0114] Schematic diagram of the structure of eGFP-encoding circular RNA Figure 3 shown.

[0115] 3. Expression detection

[0116] 1) Preparation of circular RNA

[0117] pET28a(+)-circ-RBS-eGFP and pET28a(+)-circ-CVB3-eGFP were linearized using XhoI enzyme and recovered using a gel excision and recovery kit (Yeasen, 19101ES70) to serve as templates for in vitro transcription. In vitro transcription was performed using the TranscriptAidT7 High Yield Transcription Kit (Thermo Fisher Scientific, K0441) according to the manufacturer's instructions to generate linear RNAs (lin-RBS-eGFP and lin-CVB3-eGFP). Circular RNAs (RBS-circ-eGFP and CVB3-circ-eGFP) were then generated by adding a final concentration of 2 mM GTP and reacting at 55°C for 15 minutes. Subsequently, uncircularized linear RNAs (lin-RBS-eGFP and lin-CVB3-eGFP) were removed by digestion with RNase R (Geneseed, R0300). The reaction system and procedures were performed according to the manufacturer's instructions. The treated RNA was mixed with 2.5 volumes of ethanol and 0.1 volumes of 3M sodium acetate (pH 5.2). After incubation at -20°C for 1 hour, the precipitated RNA was collected by centrifugation at 12,000 g for 30 minutes at 4°C. The RNA was washed with 1 mL of 75% ethanol and then centrifuged again at 12,000 g for 10 minutes at 4°C. After air drying, the resulting circular RNA (circ-RBS-eGFP and circ-CVB3-eGFP) was dissolved in DEPC water.

[0118] 2) Construction of liposome system

[0119] The lipids used in this example were provided by AVT Biotech (Shanghai) Co., Ltd. The formulation of LNP includes ionizable lipid 1-octylnonyl 8-[(2-hydroxyethyl)[6-oxo-6- (undecyloxy)hexyl]amino]-octanoate (SM-102; AVT, O02010), 1,2-distearoyl-sn-glycero-3- phosphocholine (DSPC; AVT, S01005), DC-Cholesterol (AVT, O02003), and 1,2-distearoyl-sn- glycero-3-phosphoethanolamine-N-[(polyethylene glycol)-2000] (DSPE-PEG2000; AVT, O02005). Specifically, 150 μg of circular RNA (RBS-circ-eGFP or CVB3-circ-eGFP) was diluted with DEPC water to 1 μg / μL. 50 mM citric acid buffer (pH 4.0) was added to a total volume of 900 μL to prepare the aqueous phase. SM-102, DSPC, cholesterol and DSPE-PEG2000 were mixed at a molar ratio of 50:10:37.5:2.5 and dissolved in anhydrous ethanol. The ethanol phase was prepared using a microfluidic device (Micro & Nano) (the amount of each component is shown in Table 1), and then the aqueous phase and the ethanol phase were mixed at a volume ratio of 3:1 at a rate of 12 mL / min to self-assemble into circular RNA (circ-RBS-eGFP and circ-CVB3-eGFP)-LNP. The freshly prepared circular RNA (circ-RBS-eGFP and circ-CVB3-eGFP)-LNP was dialyzed against 1x PBS buffer at room temperature for 2 hours to remove ethanol and exchange the buffer, and then sterilized by a 0.22 μm filter.

[0120] Table 1

[0121] Components Dosage SM102(O02010,AVI) 88.8μL DC-cholesterol (O02003, AVI) 72.4μL DSPC(S01005,AVI) 39.6μL DSPE-PEG2000 7.6μL Anhydrous ethanol 791.6μL

[0122] 3) Transfection

[0123] 3*10 4 ^6 cells were plated in a 12-well plate, and after 24 hours, 100 μL of circular RNA (circ-RBS-eGFP or circ-CVB3-eGFP)-LNP was mixed with complete medium (DMEM medium + 10% serum) and incubated at 37°C, 5% CO2 for 48 hours, and green fluorescence was observed.

[0124] The experimental results are shown in Figure 4 Table 2. circ-RBS-eGFP cannot be expressed in eukaryotic cells (293T), but circ-CVB3-eGFP can be expressed in eukaryotic cells (293T).

[0125] comprehensive Figure 2 and 4 The results confirmed that RBS mediates specific translation in bacteria.

[0126] Example 4 LNP delivery effect verification

[0127] E. coli (BL21) cells were diluted to an OD600 of 0.1. 100 μL of the bacterial suspension was mixed with 100 μL of the circular circ-RBS-eGFP-LNP. The cells were incubated at 37°C, 220 rpm, for 0 and 5 minutes, followed by centrifugation at 5000 rpm for 2 minutes, and the supernatant was discarded. The pellet was washed with 1 mL of PBS, centrifuged at 5000 rpm for 2 minutes, and the supernatant discarded. This process was repeated three times. Then, 1 mL of Trizol was added and the mixture was allowed to stand at room temperature for 5 minutes. 0.2 mL of chloroform was added, the mixture was gently shaken, allowed to stand at room temperature for 2 minutes, and then centrifuged at 10,000 g for 10 minutes at 4°C to separate the layers. The upper aqueous layer was transferred to an RNase-free centrifuge tube, and 0.5 mL of isopropanol was added to precipitate the RNA. After standing at room temperature for 10 minutes, the precipitated RNA was collected by centrifugation at 12,000 g for 30 minutes at 4°C. The RNA was washed with 1 mL of 75% ethanol and centrifuged again at 12,000 g for 10 minutes at 4°C to collect the RNA. After air drying, the resulting RNA was dissolved in 32 μL of DEPC water and used as a template for RT-PCR.

[0128] The RT-PCR detection process was carried out according to the instructions of the RT-PCR kit (11139ES60) of Yisheng Company. The relevant primer sequences are as follows:

[0129] eGFP reverse transcription primer: AGTGCGGCCGCCAAAAAACCCCTCAAGACCCGTTTAGA (SEQ ID NO: 13);

[0130] 16S rRNA-faw primer: GTTAATACCTTTGCTCATTGA (SEQ ID NO: 14);

[0131] 16S rRNA-rev primer: CCTCCAGATCTCTACGCATTT (SEQ ID NO: 15);

[0132] GFP-faw primer: GAATTCGTGAGCAAGGGCGAG (SEQ ID NO: 16);

[0133] GFP-rev primer: AAGCTTTTACTTGTACAGCTCGTCCAT (SEQ ID NO: 17).

[0134] The results of RT-PCR were analyzed by agarose electrophoresis.

[0135] The results are as follows Figure 5 As shown, lin-RBS-eGFP and circ-RBS-eGFP were encapsulated by LNPs and incubated with E. coli (BL21) at 37°C for 5 minutes. RT-PCR results showed that LNPs were able to successfully deliver RNA into E. coli.

[0136] Example 5 Construction of bacteria-specifically expressed GZMB circular RNA

[0137] 1. Construction of pET28a(+)-circ-RBS-GZMB

[0138] In this example, a bacterial-specific expression of GZMB circular RNA in vitro transcription template plasmid pET28a(+)-circ-RBS-GZMB was constructed. The plasmid includes a bacterial ribosome binding site (RBS) (SEQ ID NO: 1), a GZMB coding sequence (nucleotide sequence of SEQ ID NO: 2, amino acid sequence of SEQ ID NO: 3), a coding sequence, and a T4 phage td gene intron cyclization sequence (SEQ ID NO: 8 and SEQ ID NO: 9). The complete sequence is shown in SEQ ID NO: 18.

[0139] 1) SEQ ID NO: 18 was synthesized by Sangon Biotech (Shanghai) Co., Ltd. and double-digested with XbaI and XhoI enzymes, and recovered using a gel excision recovery kit (Yeasen, 19101ES70).

[0140] 2) The pET28a(+) plasmid was double-digested with XbaI and XhoI enzymes, and the fragments were recovered by gel excision using a gel recovery kit (Yeasen, 19101ES70).

[0141] 3) Use T4 DNA ligase to ligate the fragments at 16°C for 2 hours. Use the ligation solution to directly transform competent E. coli (DH5α) cells. Plate the transformed E. coli (DH5α) cells on solid LB medium supplemented with 50 μg / mL kanamycin and culture overnight at 37°C. Single colonies were picked from the culture medium, and the plasmids were extracted and sequenced. The plasmid that was sequenced correctly was pET28a(+)-circ-RBS-GZMB.

[0142] circ-RBS-GZMB:

[0143]

[0144] Schematic diagram of the structure of GZMB-encoded circular RNA specifically expressed by bacteria Figure 6 shown.

[0145] 2. Construction of circular RNA

[0146] pET28a(+)-circ-RBS-GZMB was linearized using XhoI enzyme and recovered using a gel excision and recovery kit (Yeasen, 19101ES70) for use as a template for in vitro transcription. In vitro transcription was performed using the TranscriptAid T7 High Yield Transcription Kit (Thermo Fisher Scientific, K0441) according to the manufacturer's instructions to generate linear RNA (lin-RBS-GZMB). A final concentration of 2 mM GTP was added and the reaction was carried out at 55°C for 15 minutes to generate circular RNA (RBS-circ-GZMB). Subsequently, uncircularized linear RNA (lin-RBS-GZMB) was removed by digestion with RNase R (Geneseed, R0300). The reaction system and procedures were performed according to the manufacturer's instructions. The treated RNA was then mixed with 2.5 volumes of ethanol and 0.1 volumes of 3 M sodium acetate (pH 5.2). The mixture was allowed to stand at -20°C for 1 hour, and the precipitated RNA was collected by centrifugation at 12,000 g for 30 minutes at 4°C. The RNA was washed with 1 mL of 75% ethanol and centrifuged again at 12,000 g for 10 minutes at 4°C. After air drying, the resulting circular RNA (circ-RBS-GZMB) was dissolved in DEPC water.

[0147] 3. Construction of LNP vector

[0148] The preparation method is the same as Example 4.

[0149] 150 μg of circular RNA (circ-RBS-GZMB) was diluted to 1 μg / μL with DEPC water. 50 mM citrate buffer (pH 4.0) was added to a total volume of 900 μL to prepare an aqueous phase. SM-102, DSPC, cholesterol, and DSPE-PEG2000 were mixed at a molar ratio of 50:10:37.5:2.5, respectively, and dissolved in anhydrous ethanol. An ethanol phase was prepared using a microfluidic device (Micro&Nano) (the amounts of each component are shown in Table 1). The aqueous and ethanol phases were then mixed at a volume ratio of 3:1 at a rate of 12 mL / min to self-assemble into circular RNA (circ-RBS-GZMB)-LNPs. Freshly prepared circular RNA (circ-RBS-GZMB)-LNPs were dialyzed against a cellulose membrane with a molecular weight cutoff of 3.5 kDa (Yuanye, MD3544) at room temperature for 2 h against 1× PBS buffer to remove ethanol and exchange the buffer, and then sterilized by passing through a 0.22 μm filter.

[0150] Based on a similar method, linear RNA (lin-RBS-GZMB)-LNP was prepared.

[0151] 4. Measurement of particle size and polydispersity index

[0152] The circular RNA (circ-RBS-GZMB)-LNP was dialyzed for 2 hours in phosphate buffered saline (PBS) containing 30% (mass-volume ratio) sucrose at pH 7.4, diluted 20-fold, and the particle size and polydispersity index (PDI) were measured using a Malvern Zetasizer Nano-ZS ZEN 3600. Figure 6 shown.

[0153] 5. Detection of the encapsulation efficiency of LNP-encapsulated RNA

[0154] The Quant-iT RiboGreen RNA assay (ThermoFisher, R11490) was used for detection. The specific steps are as follows:

[0155] 1) Prepare 1% TE buffer and 2% TE-Triton buffer (prepared with 1% TE buffer and Triton-100) as needed;

[0156] 2) Prepare standards (n = 3) at dilutions of 0 μg / mL, 0.05 μg / mL, 0.1 μg / mL, 0.2 μg / mL, 1 μg / mL, and 2 μg / mL (diluted with 1% TE buffer);

[0157] 3) Prepare LNP-RNA complex samples and dilute them into three concentrations:

[0158] LNP-RNA 1% TE buffer 2% TE-Triton buffer 3μL 297μL 297μL 6μL 294μL 294μL 12 μL 288μL 288μL

[0159] 4) Prepare the required working solution by diluting the RiboGreen dye in the kit 200-fold with 1% TE buffer. Prepare 8000 μL of the working solution, i.e., 40 μL of RiboGreen dye is diluted with 7960 μL of 1% TE buffer.

[0160] 5) This assay requires an opaque 96-well plate. 100 μL of each standard and sample are added to the plate, followed by 100 μL of working solution. The reaction is allowed to proceed at room temperature for 2-5 minutes.

[0161] 6) Measure the fluorescence intensity of the standard sample using a microplate reader with an excitation wavelength of 480 nm, an emission wavelength of 520 nm, a gain of 55, and a detection height of 8 mm.

[0162] 7) Make a standard curve and substitute it into the formula to calculate the encapsulation efficiency.

[0163] Encapsulation efficiency (%) = (RNA amount in 2% TE-Triton buffer - RNA amount in 1% TE buffer) / RNA amount in 2% TE-Triton buffer.

[0164] According to this method, the average encapsulation efficiency was determined to be 90.6%.

[0165] Example 6 Bactericidal effect detection

[0166] Dilute E. coli (BL21) or S. aureus (RN4220) to OD600 = 0.1, take 100 μL of the bacterial solution, and perform the experiment according to the following groupings:

[0167] 1) No treatment; 2) Mixed with 100 μL of empty LNP; 3) Mixed with 100 μL of lin-RBS-GZMB-LNP; 4) Mixed with 100 μL of circ-RBS-GZMB-LNP. After incubation at 37°C, 220 rpm for 1 hour, 20 μL of the mixture was spread on LB plates and cultured at 37°C for 12 hours. Colonies were counted.

[0168] The results are as follows Figure 8 Among them, lin-RBS-GZMB-LNP and circ-RBS-GZMB-LNP both had good bactericidal effects, and circ-RBS-GZMB-LNP had the best bactericidal effect, with significant differences.

[0169] Example 7 Effect of RBS-circ-GZMB-LNP on Cellular Immune Response

[0170] Take 3*10 4 Mouse macrophages (RAW 264.7), mouse muscle cells (C2C12), or human embryonic kidney cells (293T) were plated in 12-well plates. After 24 hours, the following groups were assigned: 1) No treatment; 2) 100 μL of Poly(I:C) was mixed with 1 mL of complete culture medium (DMEM medium with 10% serum); 3) 100 μL of lin-RBS-GZMB was mixed with 1 mL of complete culture medium (DMEM medium with 10% serum); and 4) 100 μL of circ-RBS-GZMB was mixed with 1 mL of complete culture medium (DMEM medium with 10% serum). After incubation at 37°C, 5% CO₂, for 12 hours, the culture medium was discarded. Then, 0.5 mL of Trizol was added, the tubes were allowed to stand at room temperature for 5 minutes, and the tubes were transferred to RNase-free 1.5 mL centrifuge tubes. 0.2 mL of chloroform was added, the tubes were gently shaken, allowed to stand at room temperature for 2 minutes, and then centrifuged at 10,000 g for 10 minutes at 4°C to separate the layers. After separation, the upper aqueous layer was transferred to an RNase-free centrifuge tube and 0.5 mL of isopropanol was added to precipitate the RNA. After standing at room temperature for 10 minutes, the precipitated RNA was collected by centrifugation at 12,000 g for 30 minutes at 4°C. The RNA was washed with 1 mL of 75% ethanol and centrifuged again at 12,000 g for 10 minutes at 4°C. After air drying, the resulting RNA was dissolved in 32 μL of DEPC water. The RNA was used as a template for RT-PCR.

[0171] The RT-PCR detection process was carried out according to the instructions of the RT-PCR kit of Yeasen (11139ES60).

[0172] The primers used for detecting the expression levels of inflammatory factors are as follows:

[0173] Actin-b-faw primer: GGCTGTATTCCCCTCCATCG (SEQ ID NO: 19);

[0174] Actin-b-rev primer: CCAGTTGGTAACAATGCCATGT (SEQ ID NO: 20);

[0175] IL6-faw primer: TAGTCCTTCCTACCCCAATTTCC (SEQ ID NO: 21);

[0176] IL6-rev primer: TTGGTCCTTAGCCACTCCTTC (SEQ ID NO: 22);

[0177] IFNβ-faw primer: CAGCTCCAAGAAAGGACGAAC (SEQ ID NO: 23);

[0178] IFNβ-rev primer: GGCAGTGTAACTCTTCTGCAT (SEQ ID NO: 24);

[0179] TNFα-faw primer: AAACACAAGATGCTGGGACA (SEQ ID NO: 25);

[0180] TNFα-rev primer: TTGATGGTGGTGCATGAGAG (SEQ ID NO: 26).

[0181] The results of qRT-PCR are as follows Figure 9 shown.

[0182] After circ-RBS-GZMB was encapsulated by LNP, it was incubated with mouse macrophages (RAW 264.7), mouse muscle cells (C2C12), and human embryonic kidney cells (293T) at 37°C for 1 hour. After 12 hours of culture, the cells were collected, total RNA was extracted, and the expression levels of immune factors were detected by qRT-PCR. The results showed that circ-RBS-GZMB or lin-RBS-GZMB-LNP did not cause significant immune response ( Figure 9 ).

Claims

1. A truncated form of granzyme B protein, characterized in that: The amino acid sequence of the granzyme B protein is shown in SEQ ID NO:

3.

2. A DNA molecule, characterized in that: The DNA molecule comprises a bacterial ribosome binding site, a cyclization sequence, and a sequence encoding the truncated form of the granzyme B protein according to claim 1.

3. The DNA molecule according to claim 2, characterized in that: The nucleotide sequence of the DNA molecule is shown in SEQ ID NO:

18.

4. An RNA molecule, characterized in that: The RNA molecule comprises a bacterial ribosome binding site, a cyclization sequence, and a sequence encoding the truncated form of the granzyme B protein according to claim 1.

5. The RNA molecule according to claim 4, characterized in that: The RNA molecule is a linear RNA; or The RNA molecule is a circular RNA obtained by circularization treatment.

6. The method for preparing the RNA molecule according to claim 4 or 5, characterized in that: The RNA molecule is obtained by transcribing the DNA molecule according to claim 2 or 3; Preferably, the transcription further includes a circularization step.

7. A carrier, characterized in that: The invention comprises the DNA molecule according to claim 2 or 3, and a vector backbone.

8. A delivery system, characterized in that: The delivery system comprises the RNA molecule according to claim 4 or 5, and liposomes.

9. Use of the RNA molecule according to claim 4 or 5 and the delivery system according to claim 8 in the preparation of a sterilization product.

10. A bactericidal drug, characterized in that: The drug comprises the RNA molecule according to claim 4 or 5, the delivery system according to claim 8, and pharmaceutically acceptable excipients.

Citation Information

Patent Citations

  • Engineered circRNA (Ribonucleic Acid) for coding NGF (Nuclear Growth Factor) protein, pharmaceutical composition as well as preparation method and application of engineered circRNA

    CN117821508A

  • Antimicrobial peptides

    US5447914A